# Pharmacokinetics and Safety of Single-Dose Sotrovimab in High-Risk Children and Adolescents With Mild-to-Moderate COVID-19

**Authors:** Jennifer Moore, Daren Austin, Alicia Aylott, Jerzy Daniluk, Leah A Gaffney, Marjan Hezareh, Ahmed Nader, Nadia Noormohamed, Charlene Parado, Amanda Peppercorn, Yessica Sachdeva, Scott Segal, Klaudia Steplewski, Phillip J Yates, Jill Walker, Andrew Skingsley

PMC · DOI: 10.1093/jpids/piaf027 · Journal of the Pediatric Infectious Diseases Society · 2025-03-27

## TL;DR

This study shows that sotrovimab is safe and has similar effects in adolescents as in adults for treating mild-to-moderate COVID-19.

## Contribution

The study provides new safety and pharmacokinetic data for sotrovimab in high-risk children and adolescents.

## Key findings

- Sotrovimab was well tolerated in children and adolescents with mild-to-moderate COVID-19.
- Pharmacokinetic parameters in adolescents were similar to those in adults.

## Abstract

Sotrovimab was well tolerated by children/adolescents (6 to <18 years) with mild-to-moderate COVID-19 at high risk of progression to severe disease. Pharmacokinetic parameters in adolescents (12 to <18 years) were generally similar to those reported in adult studies of sotrovimab.

## Linked entities

- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** COVID-19 (MESH:D000086382)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12084821/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12084821/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC12084821/full.md

---
Source: https://tomesphere.com/paper/PMC12084821